Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients with Ulcerative Colitis: A GETAID Multicentre Cohort Study.

Antoine Meyer Mathurin Fumery 1, 2 Laurent Peyrin-Biroulet 3, 4 Jérôme Filippi 5 Romain Altwegg 6 Yoram Bouhnik 7 Mélanie Serrero 8 David Laharie 9, 10 Xavier Roblin 11 Maria Nachury 12 Vered Abitbol 13 Guillaume Cadiot 14 Stéphane Nancey 15 Matthieu Allez 16 Cyrielle Gilletta 17 Lucine Vuitton 18 Guillaume Savoye 19, 20, 21, 22 Stephane Nahon 23 Anne Bourrier 24 Anthony Buisson 25 Guillaume Bouguen 3, 4 Arnaud Bourreille 26 Stéphanie Viennot 27 Franck Carbonnel 28 Aurélien Amiot 29 
Abstract : INTRODUCTION: There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. METHODS: We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events. Propensity scores weighted comparison was applied. RESULTS: In total, 121 patients were included in the vedolizumab group and 97 were included in the ustekinumab group. At week 14 and week 52, in the weighted cohort, no difference was found between vedolizumab and ustekinumab for steroid-free clinical remission (OR = 0.55 [0.21-1.41], p\,=\,.21 and 0.94 [0.40-2.22], p\,=\,.89, respectively). There was no difference between vedolizumab and ustekinumab for secondary outcomes such as clinical remission, hospitalization, UC-related surgery, treatment persistence and serious and infectious adverse events. CONCLUSION: In patients with UC for whom anti-TNF therapy failed, no difference was found between vedolizumab and ustekinumab after propensity scores weighted comparison. Further studies are required to determine predictive factors of the efficacy of both biological agents.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03723440
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : jeudi 14 juillet 2022 - 17:24:15
Dernière modification le : vendredi 5 août 2022 - 12:00:25

Identifiants

Citation

Antoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, Jérôme Filippi, Romain Altwegg, et al.. Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients with Ulcerative Colitis: A GETAID Multicentre Cohort Study.. Scandinavian journal of gastroenterology, 2022, pp.1--9. ⟨10.1080/00365521.2022.2095668⟩. ⟨hal-03723440⟩

Partager

Métriques

Consultations de la notice

0